When compared with previous EGFR kinase inhibitors, osimertinib shows significantly less in vitro activity against wild-type EGFR and great efficacy for patients with advanced/metastatic NSCLC who developed EGFRT790M mutation, following progression on first and second classes of TKIs targeting EGFR. This evidence concerns the gene EGFR and non-small cell lung carcinoma.